Guidance includes impact of Arizona market entry, and assumes no other new business development activity De minimis capital expenditures expected in full-year 2025 At least 80% of Adjusted EBITDA ...

Enovis also reported second-quarter net loss of $37 million, or a loss of 6.5% of sales, and adjusted EBITDA of $97 million, or 17.2% of sales. The Company reported second-quarter 2025 net loss from ...

SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic ...

The conference call will be held on Thursday, 28 August 2025 at 3pm CEST / 2pm BST / 9am EDT / 6am PDT as a Teams webinar. To attend the webcast, register via this link. Please complete the ...

The FDA decision follows the announcement in July by the European Medicines Agency (EMA) 1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough ...

Strong underlying sales growth was underpinned by the double-digit performance from our biosimilars which, in the second quarter, represented 30% of net sales for the first time, marking a true ...

In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the revolving credit facility has been corrected ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, ...

The conference call can be accessed using the following information: Webcast: Click here Date: Wednesday, August 13, 2025 – 4:30 p.m. ET Domestic: (877) 407-0832 International: (201) 689-8433 ...

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following ...

“We’re thrilled to welcome Dr. Tarnoff to our Board during this pivotal phase of growth,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “His leadership and expertise in clinical ...

Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4 ...